Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 19/20 | 0.64 |
| ▸ | CDK1 | P06493 | 19/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 15/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2595420 | 1.00 | AURKA (0.64) | AURKACDK1AURKBCCNB1CYP3A4 | |
| SCHEMBL14957677 | 0.88 | JAK1 (0.58) | AURKACDK1AURKBCCNB1JAK2 | |
| SCHEMBL2589195 | 0.88 | JAK2 (0.52) | AURKACDK1AURKBCCNB1CYP3A4 | |
| SCHEMBL2589136 | 0.87 | AURKA (0.51) | AURKACDK1AURKBCCNB1JAK2 | |
| SCHEMBL14957880 | 0.87 | AURKA (0.51) | AURKACDK1AURKBCCNB1JAK2 | |
| SCHEMBL12174882 | 0.87 | AURKA (0.51) | AURKACDK1AURKBCCNB1JAK2 | |
| SCHEMBL14957455 | 0.86 | AURKA (0.50) | AURKACDK1AURKBCCNB1JAK2 | |
| SCHEMBL12174914 | 0.85 | AURKA (0.48) | AURKACDK1AURKBCCNB1JAK2 | |
| SCHEMBL14958030 | 0.85 | AURKA (0.48) | AURKACDK1AURKBCCNB1JAK2 | |
| SCHEMBL14958022 | 0.85 | AURKA (0.48) | AURKACDK1AURKBCCNB1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | claimed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2566867-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011134831-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | AURKA 406/4885CDK1 26/4885AURKB 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.